Guideline for the Diagnosis and Treatment of Asthma – Addendum 2020 Guideline of the German Respiratory Society and the German Atemwegsliga in Cooperation with the Paediatric Respiratory Society and the Austrian Society of Pneumology

The present addendum of the guideline for the diagnosis and treatment of asthma (2017) complements new insights into the diagnosis and management of asthma as well as for the newly approved drugs for the treatment of asthma. Current, evidence-based recommendations on diagnostic and therapeutic approaches are presented for children and adolescents as well as for adults with asthma.

[1]  I. Pavord,et al.  Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. , 2020, The Lancet. Respiratory medicine.

[2]  C. Gessner,et al.  Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). , 2020, Respiratory medicine.

[3]  Y. Gon,et al.  Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.

[4]  H. Kerstjens,et al.  Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. , 2020, The Lancet. Respiratory medicine.

[5]  M. Lommatzsch.  Immune Modulation in Asthma: Current Concepts and Future Strategies , 2020, Respiration.

[6]  H. Tillmann,et al.  A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma. , 2020, Pulmonary pharmacology & therapeutics.

[7]  H. Watz,et al.  Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study , 2020, Respiratory Research.

[8]  C. Janson,et al.  Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme , 2020, European Respiratory Journal.

[9]  P. D’Andrea,et al.  Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings. , 2020, Respiratory medicine.

[10]  C. Bachert,et al.  Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials , 2020 .

[11]  J. Virchow,et al.  Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials , 2019, The Lancet.

[12]  R. Hancox,et al.  Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial , 2019, The Lancet.

[13]  A. Sheikh,et al.  GINA 2019: a fundamental change in asthma management , 2019, European Respiratory Journal.

[14]  I. Pavord,et al.  Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. , 2019, The New England journal of medicine.

[15]  J. Virchow,et al.  Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma , 2018, Thorax.

[16]  I. Pavord,et al.  Dupilumab Efficacy and Safety in Moderate‐to‐Severe Uncontrolled Asthma , 2018, The New England journal of medicine.

[17]  K. Rabe,et al.  Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma , 2018, The New England journal of medicine.

[18]  E. Bateman,et al.  As‐Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma , 2018, The New England journal of medicine.

[19]  E. Bateman,et al.  Inhaled Combined Budesonide–Formoterol as Needed in Mild Asthma , 2018, The New England journal of medicine.

[20]  C. White,et al.  Association of Inhaled Corticosteroids and Long-Acting &bgr;-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis , 2018, JAMA.

[21]  E. Israel,et al.  Severe and Difficult‐to‐Treat Asthma in Adults , 2017, The New England journal of medicine.

[22]  G. Yancopoulos,et al.  Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial , 2017, The Lancet.

[23]  K. Rabe,et al.  Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma , 2017, The New England journal of medicine.

[24]  Á. Cruz,et al.  Revisiting Type 2‐high and Type 2‐low airway inflammation in asthma: current knowledge and therapeutic implications , 2017, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[25]  W. Busse,et al.  Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study , 2017, The Lancet.

[26]  W. Busse,et al.  Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial , 2016, The Lancet.

[27]  H. Neffen,et al.  Systematic review on the use of omalizumab for the treatment of asthmatic children and adolescents , 2015, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

[28]  Christian Schmid-Egger,et al.  Neue Literatur , 2005, Archiv für Entwicklungsmechanik der Organismen.

[29]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .